Cite
HARVARD Citation
Shankar, R. et al. (2017). A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Current medical research and opinion. pp. 1853-1860. [Online].